Shots:

• The P-II PULSAR trial involves assessing Sotatercept (0.3 mg/kg or 0.3 mg/kg- SC- q3w) vs PBO in 106 patients in a ratio (3:3:4) with PAH. The results were published in NEJM
• The results of the P-II PULSAR study that demonstrated sotatercept has the potential to provide benefits to patients with PAH on top of currently available therapies. The 1EPs @ 24week trial- showed improvement in pulmonary vascular resistance and 2EPs showed mean improvement from a baseline of six-min walk distance- was well-tolerated
• The company is planning two additional P-III studies of HYPERION and ZENITH in newly diagnosed patients and with WHO functional class IV disease to treat PAH. Additionally- the P-III STELLAR trial is ongoing

  Ref: BusinessWire | Image: BusinessWire